


Multicenter Clinical Trials Confirming Sustained Efficacy

Two-year results from an **on-going multicenter trial in Asia** indicate that both ZEISS MyoCare and ZEISS MyoCare S lenses continue to significantly slow myopia progression compared to single vision lenses.

One-year results from an **on-going multicenter trial in Europe** show that ZEISS MyoCare lenses significantly slowed myopia and reduced the risk of fast progression (defined as $-0.50D$ or greater over 12 months) compared to single vision lenses. Additionally, ZEISS MyoCare lenses also slowed myopia compared to progression before use of ZEISS MyoCare.



Comparison of one-year results between Asian and European populations indicated that ZEISS MyoCare was **equally effective across different ethnicities**.

Clinical Context

The **global prevalence of myopia and high myopia is rising**, causing substantial health and financial burden. With strategies employed to prevent and slow the progression of myopia, it is crucial to **establish efficacy from robust evaluations**


involving diverse ethnic groups, large samples, multiple locations, and long study periods. In **two on-going, prospective, double-masked, parallel-group, multicenter clinical trials across China and Europe**, ZEISS MyoCare lenses are being evaluated for

their effectiveness in slowing myopia. Results from both trials were presented at the **2025 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO)**, May 4th to 8th in Salt Lake City, Utah, USA.

Key Results - Myopia progression in SE and AL

ASIAN EYES

After two years of lens wear, compared to single vision (SV) lenses, **progression of myopia was significantly slower** with ZEISS MyoCare and ZEISS MyoCare S lenses. The difference in progression between MyoCare, MyoCare S and SV lenses for spherical equivalent refractive error (SE) and axial length (AL) were¹



EUROPEAN EYES


Over 12 months, compared to single vision lenses, ZEISS MyoCare lenses led to a reduction of myopia progression by an average of²

➤ Reduction of fast progressors

Significantly less ZEISS MyoCare wearers exhibited fast progression³.

➤ Tolerability and subjective feedback

Subjective ratings indicate that children adapted to ZEISS MyoCare lenses. Assessments after one week indicate that vision (including distance vision, near vision, vision during sports and daily activities) was overall rated as good to very good⁴.



Additionally, compared to past SE progression, ZEISS MyoCare effectively slowed myopia compared to SV, and this was irrespective of age of the individual⁵.

Efficacy in Asian versus European Eyes

Comparison between Asian and European children **confirmed that 1-year progression was higher with SV lenses in Asian children. Despite this difference, ZEISS MyoCare lenses were effective in slowing myopia equally across both ethnicities.**

References

- Chen, X., et al. (2025, May 4-8). Slowing myopia progression with cylindrical annular refractive elements (CARE) – results from a 2-year prospective multicenter trial. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Salt Lake City, UT, United States.
- Alvarez-Peregrina, C., et al. Clinical Evaluation of MyoCare in Europe – the CEME Study Group. Clinical evaluation of MyoCare in Europe (CEME) for myopia management: One-year results. Ophthalmic Physiol Opt. 2025 Apr 29. doi: 10.1111/opo.13517. Epub ahead of print. PMID: 40296784.
- Alvarez-Peregrina, C., et al. (2025, May 4-8). Analysis of fast myopia progression and eye growth reversal in the Clinical Evaluation of MyoCare in Europe (CEME) study after 12 months wearing CARE lenses. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Salt Lake City, UT, United States.
- Sanchez-Tena, M.A., et al. (2025, May 4-8). Adaptation and Visual Performance of CARE Spectacle Lenses: Findings from the Clinical Evaluation of MyoCare in Europe (CEME) Study. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Salt Lake City, UT, United States.
- Ohlendorf, A., et al. (2025, May 4-8). Myopia progression in children: Comparison of progression one year before and during participation in a randomized controlled clinical trial. [Conference presentation abstract]. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, Salt Lake City, UT, United States.